- Home
- GLRE vs ADCT Comparison
GLRE vs ADCT Comparison
Compare GLRE & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- ADCT
- Stock Information
- Founded
- GLRE 2004
- ADCT 2011
- Country
- GLRE Cayman Islands
- ADCT Switzerland
- Employees
- GLRE N/A
- ADCT N/A
- Industry
- GLRE Property-Casualty Insurers
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- GLRE Finance
- ADCT Health Care
- Exchange
- GLRE Nasdaq
- ADCT Nasdaq
- Market Cap
- GLRE 439.8M
- ADCT 398.2M
- IPO Year
- GLRE 2007
- ADCT 2020
- Fundamental
- Price
- GLRE $12.65
- ADCT $3.26
- Analyst Decision
- GLRE
- ADCT Strong Buy
- Analyst Count
- GLRE 0
- ADCT 6
- Target Price
- GLRE N/A
- ADCT $7.80
- AVG Volume (30 Days)
- GLRE 133.6K
- ADCT 545.2K
- Earning Date
- GLRE 11-03-2025
- ADCT 11-06-2025
- Dividend Yield
- GLRE N/A
- ADCT N/A
- EPS Growth
- GLRE N/A
- ADCT N/A
- EPS
- GLRE 1.10
- ADCT N/A
- Revenue
- GLRE $695,657,000.00
- ADCT $77,246,000.00
- Revenue This Year
- GLRE N/A
- ADCT $13.10
- Revenue Next Year
- GLRE N/A
- ADCT $6.23
- P/E Ratio
- GLRE $11.43
- ADCT N/A
- Revenue Growth
- GLRE 0.97
- ADCT 15.73
- 52 Week Low
- GLRE $12.14
- ADCT $1.05
- 52 Week High
- GLRE $15.82
- ADCT $3.97
- Technical
- Relative Strength Index (RSI)
- GLRE 45.63
- ADCT 52.13
- Support Level
- GLRE $12.40
- ADCT $3.15
- Resistance Level
- GLRE $12.74
- ADCT $3.38
- Average True Range (ATR)
- GLRE 0.27
- ADCT 0.17
- MACD
- GLRE 0.00
- ADCT -0.01
- Stochastic Oscillator
- GLRE 37.50
- ADCT 39.45
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).